
|Articles|November 1, 2012
Greater knowledge of B cell autoimmunity allows for specific targeting
As research continues to explore B cell autoimmunity, B cell-mediated therapies likely will pursue increasingly specific targets, says Arthur Kavanaugh, M.D.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
AbbVie Files for Vitiligo Indication, Putting Systemic Therapy Under Regulatory Review
2
UCB Presents 3-Year BE HEARD Trial Results for Bimekizumab in Moderate-to-Severe HS
3
Kicking Off MOPD 2026 With Lawrence Schachner, MD
4
Sagimet and Ascletis Report Positive 52-Week Safety and Efficacy Data for Denifanstat in Acne
5











